Proposed U.S. guidelines may make it easier for drug companies to test Alzheimer's treatments in people at an earlier stage, when scientists think they may have the best shot at working. The draft guidance document, issued on Thursday by the U.S. Food and Drug Administration, reflects changes in scientists' understanding of Alzheimer's. They now believe the disease begins at least a decade before symptoms appear.